Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

315.31
+2.430.78%
Post-market: 315.310.00000.00%19:46 EDT
Volume:370.00K
Turnover:117.09M
Market Cap:18.97B
PE:34.23
High:318.31
Open:313.66
Low:313.41
Close:312.88
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:1.79
T/O Rate:0.61%
Dividend:4.63
Dividend Rate:1.47%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.96
PE(LYR):7.60

Loading ...

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Exchange-Traded Funds Rise as US Equities Advance After Midday

MT Newswires Live
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

Innova Captab Files Scrutinizer’s Report and Voting Results for 22nd AGM

TIPRANKS
·
Oct 03

AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors

TIPRANKS
·
Oct 03

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Jobs Data

MT Newswires Live
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Oct 02

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Oct 02

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Oct 02

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS
·
Oct 02

J&J - 60% Scalp Psoriasis, 89% Genital Psoriasis Patients Achieve Complete Clearance at Week 112

THOMSON REUTERS
·
Oct 02

J&J - Safety Findings Through Week 112 Consistent with Icotyde Profile, no New Safety Signals

THOMSON REUTERS
·
Oct 02

The Ensign Group Adds Operations in Washington

GlobeNewswire
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Oct 02